We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
C-Reactive Protein and 5-Year Survival in Type 2 Diabetes.
- Authors
Bruno, Graziella; Fornengo, Paolo; Novelli, Giulia; Panero, Francesco; Perotto, Massimo; Segre, Olivia; Zucco, Chiara; Deambrogio, PierCarlo; Bargero, Giuseppe; Perin, Paolo Cavallo
- Abstract
OBJECTIVE--To determine to what extent plasma C-reactive protein (CRP) values influence 5-year all-cause and cardiovascular mortality in type 2 diabetic individuals, independently of albumin excretion rate (AER) and other cardiovascular risk factors, and its incremental usefulness for predicting individual risk of mortality. RESEARCH DESIGN AND METHODS--Measurements of CRP were performed in 2,381 of 3,249 (73.3%) subjects as part of the population-based Casale Monferrato Study. Its association with 5-year all-cause and cardiovascular mortality was assessed with multivariate Cox proportional hazards modeling. The C statistic and measures of calibration and global fit were also assessed. RESULTS--Results are based on 496 deaths in 11.717 person-years of observations (median follow-up 5.4 years). With respect to subjects with CRP ≤3 mg/1, those with higher values had an adjusted hazard ratio (HR) of 1.51 (95% CI 1.18-1.92) for all-cause mortality and 1.44 (0.99-2.08) for cardiovascular mortality. In normoalbuminuric subjects, respective HRs of CRP were 1.56 (1.13-2.15) and 1.65 (1.00-2.74), AER being neither a modifier nor a confounder of CRP association. In analysis limited to diabetic subjects without cardiovascular disease (CVD), adjusted HRs were 1.67 (1.24-2.24) for all-cause mortality and 1.36 (0.83-2.24) for cardiovascular mortality. The improvement in individual risk assessment was marginal when measured with various statistical measures of model discrimination, calibration, and global fit. CONCLUSIONS--CRP measurement is independently associated with short-term mortality risk in type 2 diabetic individuals, even in normoalbuminuric subjects and in those without a previous diagnosis of CVD. Its clinical usefulness in individual assessment of 5-year risk of mortality, however, is limited. Diabetes 58:926-933, 2009
- Subjects
C-reactive protein; TYPE 2 diabetes; ALBUMINS; CARDIOVASCULAR disease related mortality; HEALTH risk assessment
- Publication
Diabetes, 2009, Vol 58, Issue 4, p926
- ISSN
0012-1797
- Publication type
Article
- DOI
10.2337/db08-0900